Free shipping on all orders over $ 500

Tofacitinib

Cat. No. M1820
Tofacitinib Structure
Synonym:

CP-690550, Tasocitinib

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 32  USD40 In stock
5mg USD 24  USD30 In stock
10mg USD 32  USD40 In stock
50mg USD 80  USD100 In stock
100mg USD 128  USD160 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

Tofacitinib (CP-690550) is a potent, small molecule inhibitor of JAK-3, which exhibiting potent effects in preclinical transplantation and arthritis models. It displays greater antiproliferative and pro-apoptotic activity against murine multipotent factor-dependent cell Patersen-erythropoietin receptor (FDCP-EpoR) cells harboring JAK2(V617F) compared with JAK2(WT). JAK-3 has been shown to play a key role in cytokine signaling via gammac, e.g. IL-2, 4, 7, 9, 15, 21. In vitro, Tofacitinib effectively inhibited a murine mixed lymphocyte reaction (MLR) (IC50= 91 nm). Mice chronically dosed with CP-690550 (1.5-15 mg/kg/day) demonstrated dose- and time-dependent alterations in lymphocyte subsets when examined by flow cytometry. The most dramatic change observed was a 96% reduction in splenic NK1.1 + TCRbeta- cell numbers following 21 days of treatment. Delayed-type hypersensitivity (DTH) responses in sensitized mice were reduced in a dose-dependent manner following treatment with the JAK-3 inhibitor (1.87-30 mg/kg, s.c.). Extended survival of neonatal Balb/c hearts implanted into the ear pinna of MHC mismatched C3H/HEN mice was observed with CP-690550 monotherapy (10-30 mg/kg/day), but improved upon combination with cyclosporin (10 mg/kg/day). Furthermore, the ability of Tofacitinib to extend cardiac allograft survival in murine models suggests it may afford a new treatment for prevention of transplant rejection.

Product Citations
Customer Product Validations & Biological Datas
Source Archives of Dermatological Research (2018). Figure 2. Tofacitinib (Abmole Bioscience, Houston, USA)
Method i.v.
Cell Lines C57BL/6 mice
Concentrations concentration of 2%
Incubation Time 21 consecutive days
Results The length of the hair infundibulum on the 21st day of the experiment was higher in groups treated topically with tofacitinib.
Source Archives of Dermatological Research (2018). Figure 1. Tofacitinib (Abmole Bioscience, Houston, USA)
Method i.v.
Cell Lines C57BL/6 mice
Concentrations concentration of 2%
Incubation Time 21 consecutive days
Results In mice treated topically with tofacitinib, 84.7% of hairs were in the anagen phase (n=72), 10.6% were in the catagen phase (n = 9), and 4.7% were in the telogen phase (n=4), where the follicles in the late anagen were located in the deep dermis and hypodermis, and follicles in the early anagen were located in the superficial dermis.
Source US Patent 9730877B2 (2017). Figure 32. Tofacitinib (Abmole Bioscience)
Method oral
Cell Lines mice
Concentrations 15 mg/kg/day
Incubation Time 12 weeks
Results None of the treated mice developed alopecia areata or cutaneous lymphadenopathy, whereas untreated mice manifested both AA and associated cutaneous lymphadenopathy
Source TJPS (2017). Figure 2. Tofacitinib (Abmole Bioscience, Houston, TX, USA)
Method qRT-PCR
Cell Lines mice hair follicle
Concentrations 2% concentration
Incubation Time 21 days
Results We investigate the expression of BMP4 which known to be an inhibitory molecule for onset of anagen entry. Quantitative real-time reverse transcription-PCR analysis showed decrease expression of BMP4 in tofacitinib treated group compare to DMSO-treated group (p-value 0.003).
Source TJPS (2017). Figure 1. Tofacitinib (Abmole Bioscience, Houston, TX, USA)
Method Inject
Cell Lines C57BL/6 male mice
Concentrations 2% concentration
Incubation Time 21 days
Results We examined the effect of topical tofacitinib on hair growth in mice tissue, tofacitinib-treated group has shown denser in thickness and length of hair follicle compared to vehicle (Figure 1A). Histology, tofacitinib treated group has shown increased in anagen hair follicle compared to vehicle (Figure 1B).
Source Arch Dermatol Res (2017). Figure 6. Tofacitinib (Abmole Bioscience, Texas, USA)
Method HE stain
Cell Lines Mice
Concentrations dissolved in DMSO to create a 2% concentration
Incubation Time 21 day
Results Tofacitinib-treated mice showed less infiltration of inflammatory cells relative to minoxidil-treated mice. In the DMSO-treated group, infiltration of several inflammatory cells infiltration was observed, while fewer inflammatory cells were observed in the ethanol-treated group.
Source Arch Dermatol Res (2017). Figure 5. Tofacitinib (Abmole Bioscience, Texas, USA)
Method HE stain
Cell Lines Mice
Concentrations dissolved in DMSO to create a 2% concentration
Incubation Time 21 day
Results More newly formed capillaries were observed in the tofacitinib-treated group than in the minoxidil- and controltreated groups, although some completely formed capillaries were observed in the minoxidil- and DMSO-treated groups.
Source Arch Dermatol Res (2017). Figure 4. Tofacitinib (Abmole Bioscience, Texas, USA)
Method HE stain
Cell Lines Mice
Concentrations dissolved in DMSO to create a 2% concentration
Incubation Time 21 day
Results "At the end of the experiment, mostly anagen hairs were observed in the tofacitinib-treated group, whereas mostly catagen and anagen hairs were observed in minoxidil- and DMSO-treated groups."
Source Science Advance (2015). Ruxolitinib, Figure 4. (AbMole Bioscience)
Method Patch assay with DP spheres
Cell Lines DP cells
Concentrations 400 nM
Incubation Time
Results In the region including genes thatwere upregulated by ruxolitinib treatment but down-regulated by tofacitinib treatment, we identified proapoptotic genes such as BAX, BCL2L11, and CASP12 (region 2).
Source Science Advance (2015). Ruxolitinib, Figure 3. (AbMole Bioscience)
Method Human HF organ culture assay
Cell Lines human HFs
Concentrations 400 nM
Incubation Time
Results We found that treatment with JAK inhibitors significantly increased the length of hair shafts when treatedwith ruxolitinib and tofacitinib, indicating a positive effect on the rate of hair elongation (P = 0.023 and P = 0.025 for tofacitinib and ruxolitinib, respectively).
Source Science Advance (2015). Ruxolitinib, Figure 1. (AbMole Bioscience)
Method Fourmice were treated with control (half of the back skin) and ruxolitinib (half of the back skin) and four mice were treated with control (half of the back skin) and tofacitinib (half of the back skin).
Cell Lines
Concentrations
Incubation Time
Results Indeed, ~90% of 8.5-week-old mice treated with ruxolitinib or tofacitinib for 5 days displayed skin darkening and hair growth within 10 days of starting treatment, whereas no hair growth was evident in control-treated mice (P < 0.0001 for ruxolitinib treatment and P = 0.04 for tofacitinib treatment). Ruxolitinib treatment enriched for the mTOR (mammalian target of rapamycin) and NFkB (nuclear factor kB) pathways, both previously shown to be involved in hair cycle regulation, whereas tofacitinib treatment enriched for pathways involved in cell motility and migration, such as Rho and integrin signaling.
Source Nature medicine (2014). Figure 1. tofacitinib (Abmole)
Method Flow cytometric analysis, Immunohistochemistry and immunofluorescence
Cell Lines
Concentrations 15 mg/kg/day
Incubation Time 12 weeks
Results "We observed complete hair regrowth within 12 weeks following topical therapy. Topical therapy was associated with a markedly reduced proportion of CD8+NKG2D+T cells in the treated skin and lymph node, normalization of the ALADIN transcriptional signature, reversal of histological markers of disease. "
Source Nature medicine (2014). Figure 3. tofacitinib (Abmole)
Method Flow cytometric analysis, Immunohistochemistry and immunofluorescence
Cell Lines
Concentrations 15 mg/kg/day
Incubation Time 12 weeks
Results we systemically administered tofacitinib at the time of grafting and found that they prevented the development of AA and the expansion of CD8+NKG2D+ T cells in all grafted recipients. The skin of mice treated with either drug showed no histological signs of inflammation. Global transcriptional analysis of whole-skin biopsies showed that both drugs also blocked the dermal inflammatory signature, as measured by Alopecia Areata Disease Activity Index.
Source Nature medicine (2014). Figure 1. JAK3i tofacitinib (Abmole)
Method grafted C3H/HeJ mice
Cell Lines CD8+NKG2D+ T cells
Concentrations 15 mg/kg/day
Incubation Time 12 weeks
Results we observed complete hair regrowth within 12 weeks following topical therapy. Topical therapy was associated with a markedly reduced proportion of CD8+NKG2D+ T cells in the treated skin and lymph node, normalization of the ALADIN transcriptional signature, reversal of histological markers of disease.
Source Nature medicine (2014). Figure 1. JAK3i tofacitinib (Abmole)
Method grafted C3H/HeJ mice
Cell Lines CD8+NKG2D+ T cells
Concentrations 15 mg/kg/day
Incubation Time 12 weeks
Results Global transcriptional analysis of whole-skin biopsies showed that both drugs also blocked the dermal inflammatory signature, as measured by Alopecia Areata Disease Activity Index
Protocol
Cell Experiment
Cell lines cytokine-dependent NK92 cell line
Preparation method (A) After cytokine starvation for 24 hours, NK92 cells were stimulated by the addition of human IL-2 for 48 hours with and without the addition of serially increasing concentrations of tofacitinib. 3H-thymidine was added during the last 6 hours of the cultures. Cells were then harvested and analyzed for 3H-thymidine incorporation. (B) Cytokine-starved NK92 cells were stimulated with human IL-2, combined IL-6/IL- 6R, or IL-12 for 48 hours with and without serially increasing concentrations of tofacitinib. (C) The NK92 cells were treated as those in panel B with and without a single 50nM dose of tofacitinib. Data are presented as means ±SD (A-C) and are representative of 3 independent experiments. (D) After cytokine starvation for 24 hours, NK92 cells were stimulated with 30 ng/mL of IL-2, 100 ng/mL of combined IL-6/IL-6R, or 100 ng/mL of IL-12 for 1 hour with and without the addition of tofacitinib. The cell lysates were immunoblotted with an anti–phospho-STAT5 monoclonal antibody and an anti-STAT5 antibody. ß-Actin was used as an input control. Data are representative of 3 independent experiments.
Concentrations 0~400 nM
Incubation time 48 h
Animal Experiment
Animal models IL-15–transgenic CD8 T-cell leukemia–bearing mice
Formulation dissolved in polyethylene glycol 300 (PEG300; VWR Scientific Products)
Dosages 50 mg/mL
Administration continuously administered via a subcutaneous mini-osmotic pump (ALZET)
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 312.37
Formula C16H20N6O
CAS Number 477600-75-2
Purity 100.00%
Solubility DMSO ≥60 mg/mL
Storage -20°C, sealed
References

[1] Papp et al. Br J Dermatol. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

[2] de Lartigue J et al. Drugs Today (Barc). Tofacitinib for the treatment of moderate to severe rheumatoid arthritis.

[3] Labranche et al. Arthritis Rheum. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.

[4] Sandborn et al. N Engl J Med. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

Related JAK Products
BMS-986202

BMS-986202 is a potent, selective, orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC50 of 0.19 nM and a Ki of 0.02 nM. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC50 of 14 μM. BMS-986202 can be used in IL-23-driven echinococcosis BMS-986202 can be used in studies of IL-23-driven echinococcosis, anti-CD40-induced colitis and spontaneous lupus.

GDC046

GDC046 (Compound 3) is a potent, selective, and orally bioavailable inhibitor of TYK2 with Ki of 4.8 nM, 83.8 nM, 27.6 nM and 253 nM for TYK2, JAK1, JAK2, and JAK3, respectively.

RO495

RO495 (CS-2667) is a potent inhibitor of Non-receptor tyrosine-protein kinase 2 (TYK2).

TG-89

TG-89 is a JAK inhibitor that inhibits JAK2, FLT3, RET and JAK3.

WYE-175765

WYE-175765 is a JAK3 and YopH inhibitor

  Catalog
Abmole Inhibitor Catalog




Keywords: Tofacitinib, CP-690550, Tasocitinib supplier, JAK, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.